Back to search

France· FR:69449143

ORGARAN 750 U.I. anti Xa/0,6 ml, solution injectable en ampoule

A danaparoid product containing danaparoïde sodique, registered in France by VIATRIS SANTE. The same ATC class is registered in 9 of our 19 countries.

ATC B01AB09

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedORGARAN 750 U.I. anti Xa/0,6 ml, solu…ATCB01AB09REGISTER NO.FR:69449143PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Danaparoid is registered in 9 of 19 countries.

Countries holding a registration under ATC B01AB09 (danaparoid), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 4 of them publish a price we can compare per daily dose

Danaparoid · ATC B01AB09

9 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Netherlands
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
DANAPAROÏDE SODIQUE
Manufacturer
VIATRIS SANTE
Country
France (FR)
ATC code
B01AB09
ATC class
Danaparoid
Defined daily dose
1.5 TSD, E
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955985686
    10 ampoule(s) en verre de 0,6 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

145 interactions on record for danaparoid.

Graded by severity as the source publishes them — 94 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Danaparoid · interactions on record

145 records

  • 94 severe
  • 51 moderate

Most severe, free to view

  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • Antithrombin IIIB01AB02severe
  • DalteparinB01AB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4ed5175b-400d-478b-a0bb-f82e657102d4
GET /v1/drugs/4ed5175b-400d-478b-a0bb-f82e657102d4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69449143",
  "date_amm": "1996-07-15",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "DANAPAROÏDE SODIQUE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "intraveineuse;sous-cutanée;voie extracorporelle autre",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about danaparoid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.